The Centre for Process Innovation (CPI) is working alongside Cobra Biologics and GE Healthcare Life Sciences on a project to support the development of cost-effective regenerative medicines.

The three-way partnership, funded by a £570,000 Innovate UK grant, aims to increase the robustness and reduce costs for the manufacturing of adeno-associated virus (AAV) vectors, a delivery vehicle used for emerging gene therapy treatments.

The gene therapy area has been developing rapidly and while only a small number of treatments are already approved for use, more than 200 clinical trials are underway.

Fore more information please go to